Introduction
Vectors derived from herpes simplex virus type 1 (HSV-1) have been shown to have broad potential for gene therapy of brain tumors. [1] [2] [3] The advantages of HSV-1 include: (1) the ability to infect a broad range of cells in both mitotic and non-mitotic phases; (2) the physical stability of the virus, allowing for on site application of high titers of virus; (3) the means for extensive genetic manipulation of the genome, so that at least 30 kb of the total 152 kb genome can be replaced by transgenes in some mutants; and (4) the capacity for selective replication in dividing cells. Replication-conditional HSV-1 mutants have been evaluated extensively in rodent models of CNS glioma. These vectors are typically deleted in one of the genes involved in viral DNA replication, encoding thymidine kinase (HSVTK), 4 ribonucleotide reductase (RR) [5] [6] [7] or uracil DNA glycosylase, 8 or in both one of the genes for these enzymes and the neurovirulence gene, ␥34.5.
9-11 The deleted function can be compensated for in dividing cells, but in nondividing cells such as neurons, the complemen-tary cellular enzymes are expressed at insufficient levels to sustain virus replication. Thus, in the brain, replication-conditional vectors propagate selectively in dividing cells, including tumor cells, reactive astrocytes and neovascularizing endothelial cells. The neurotoxicity of replication-conditional HSV-1 vectors is thereby greatly reduced as compared with wild-type virus. However, before clinical use of replication-conditional HSV-1 vectors their neurotoxicity has to be tested thoroughly in primate studies.
In contrast to laboratory rodents, which are not the natural host for HSV-1, 40-90% of all humans have antibodies against this human pathogen. 12, 13 The humoral and cellular immune response in pre-exposed patients could prove an obstacle for HSV-1-mediated gene transfer. Neutralizing antibodies could block the initial infection of target cells and the cellular immune reponse could lead to premature elimination of infected cells, thus reducing the number of transduced cells. In addition, an inflammatory response evoked by the virus in the brain could be toxic in its own right. The purpose of the present marking study was to evaluate whether, under conditions of pre-immunization, a recombinant HSV-1 vector could still deliver transgenes, such as lacZ or HSVtk, into glioma cells in rat brain and whether the inflammatory response to the virus would cause neurotoxicity. To avoid confounding effects of immunity elicited against the glioma cells themselves, a rat glioma model, D74 in syngeneic Fischer rats, was chosen which has low immunogenicity. 14 
Results

Experiments in culture
The genotype of hrR3, the recombinant HSV-1 vector used in this study, is RR − LacZ + . HrR3 was derived from the HSV-1 KOS strain by inserting the E. coli lacZ gene into the UL39 locus coding for the large subunit of the RR (infected cell protein (ICP)6). 6 The reporter gene lacZ is driven by the ICP6 early viral promoter. Rat D74 glioma cells proved relatively resistant to infection with hrR3. Sixteen hours after infection with hrR3 at a multiplicity of infection (MOI; plaque-forming units (p.f.u.) per cell) of 100, 28 ± 6.7% (mean ± standard error of mean) of the population (Ͻ30% confluent) stained lacZ positive. Five days after infection at this MOI no lacZ-positive cells were detected. Cytopathic effects were observed on day 6, and the number of viable D74 cells on hrR3-infected plates was reduced to 77 ± 12% as compared with uninfected control plates (P = 0.023). Exposure of infected cells (Ͼ60% confluent) to ganciclovir (GCV; 1 g/ml), which is converted to its cytotoxic form by HSVTK, from days 3 to 6 after infection, did not increase cell death significantly. D74 glioma cells also sustained the propagation of hrR3 poorly: the titers of progeny virus generated in dividing D74 cells remained below 20 p.f.u./ml 3 and 5 days after infection with an MOI of 100.
In contrast to the rodent D74 glioma, human glioma cells are highly infectable with HSV-1. Sixteen hours after infection of human T98G glioma cells at MOIs of 3 or 100, 53 ± 30%, or 100% of T98G cells, respectively, stained lacZ positive. Titers of neutralizing antibodies to the recombinant HSV-1 vector, hrR3 For pre-immunization, 10 8 p.f.u. hrR3 were injected intraperitoneally into Fischer rats. This elicited a marked immune reaction, as determined by serum titers of neutralizing antibodies in a complement-dependent plaque inhibition assay (Figure 1 ). Titers of neutralizing antibodies rose from a base level of у1:8 (dilution yielding a 50% reduction in plaque number) in nonimmunized animals to 1:1024 in immunized animals 9 days later, and remained at that level for at least 2 weeks. On day 21, D74 gliomas were implanted in the right frontal lobe of syngeneic rats. When tumor-bearing animals were challenged by intratumoral injection of 10 8 p.f.u. hrR3 25 days after immunization, titers of neutralizing antibodies rose further (four-fold) to 1:4096 within 2 days. Intracranial injection of the same amount of virus into nonimmunized animals induced neutralizing antibodies to a titer reaching 1:1024 within 10 days. Animals showed no apparent illness in response to the immunization procedure or to tumor inoculation.
Gene transfer by hrR3
Gene delivery to intracranial D74 glioma cells, as measured by HSVTK and ␤-galactosidase staining, was analyzed on tumor sections of animals from three different treatment groups: (1) intraperitoneal immunization (day 0) and intratumoral injection (day 25) of hrR3 (+/+); (2) intraperitoneal sham-immunization and intratumoral injection of hrR3 (−/+); and (3) intraperitoneal and intratumoral injection with medium alone (−/−) ( Table 1) . Tumors in control animals (−/−) were completely HSVTK negative 0.5-10 days after intracranial sham-treatment, but showed some weak ␤-galactosidase staining, with a peak at 2 days after intracranial sham-treatment (Table 1) . This artifactual lacZ staining is likely due to high levels of the mammalian lysosomal ␤-galactosidase expressed in macrophages 15 which invade the injection site after the sham inoculation.
Gene transfer to D74 cells during the initial period of hrR3 infection was evaluated by HSVTK and lacZ expression 12 h after intratumoral injection. The number of HSVTK-and lacZ-positive cells was reduced to 12-17% in pre-immunized animals, as compared with nonimmunized animals (Table 1; Figure 2a and b). HSVTK (Figure 2c -f) and lacZ expression stayed at about the same relative levels in pre-immunized and nonimmunized animals for 48 h after injection (Table 1) . HSVTK and ␤-galactosidase-positive cells were found in the tumor and at the tumor/parenchyma border in both −/+ and +/+ animals. Morphologically, positive cells within the tumor consisted of tumor cells and some inflammatory cells ( Figure 2a and b) ; positive cells in the surrounding parenchyma appeared to be reactive astrocytes and inflammatory cells. Additionally, HSVTK and ␤-galactosidase-positive cells were found in the subarachnoid space, probably due to leakage from the injection. Neurons did not stain positive by HSVTK immunohistochemistry, but some neurons (distant from the injection site) reacted weakly with the X-gal substrate; the high endogenous X-gal reactivity by these neurons was described previously by Rosenberg et al. 16 By day 5 after intracranial virus inoculation, HSVTK and lacZ expression in tumor cells and inflammatory cells declined markedly in both −/+ and +/+ animals (Figure 2g and h).
Inflammatory reaction within intracranial gliomas
In −/− animals there was no inflammatory response at any time-point (Figure 3a) except for a few macrophages around the needle track, which presumably reflect a nonspecific reaction related to the physical injury of the injection. Anti-ED-1 immunohistochemistry showed very little monocyte/macrophage infiltration of tumors in −/− animals.
Twelve and 24 h after intracranial virus injection, the inflammatory cell infiltrates of tumors in +/+ animals were prominent, including lymphocytes, neutrophils and macrophages (Figure 3c ). The inflammatory cells were distributed throughout the tumor and the meninges. At the same time-points, however, in −/+ animals the inflammatory infiltrate was less extensive and remained predominantly perivascular ( Figure 3b ). It consisted predominantly of lymphocytes with only a few polymorphonuclear cells. Forty-eight hours after intracranial virus injection, the inflammatory cell infiltrate was composed predominantly of lymphocytes, in both −/+ and +/+ animals. Five days after virus injection the inflammatory reaction in both −/+ and +/+ animals had diminished, but some lymphocytes and macrophages could be found in the tumor, as well as in the meninges. ED-1 macrophages cells were found to a similar extent in tumors of −/+ and +/+ animals on day 5 after intracranial virus application (Figure 3d and e). By day 10, lymphocytic infiltrates had completely resolved in both −/+ and +/+ animals. On day 10, ED-1-positive macrophages were only found in −/+ animals ( Figure 3f ), whereas ED-1-positive cells were no longer present in +/+ animals ( Figure 3g ).
Therapeutic efficacy
Two treatment studies were carried out using animals inoculated intracranially with 40 000 D74 glioma cells on day 21 and treated by intratumoral injection with 10 8 p.f.u. hrR3 or medium on day 25. In the first study, with 11 animals per treatment group, the median survival time (MST) after tumor cell implantation was 18 days (range 17-24 days) for sham-vaccinated and sham-treated animals (−/−), 20 days (range 18-22 days) for −/+ animals and 20 days (range 17-32 days) for +/+ animals. The prolongation of survival for animals treated intracranially with hrR3, as compared with untreated animals, was small (2 days or 11% of control MST), but significant (P = 0.001 and P = 0.02, for −/− versus −/+ and −/− versus +/+ groups, respectively). As a side-effect of hrR3 treatment, temporary lethargy was observed occasionally, but to the same extent in both immunized and nonimmunized animals after intracranial vector injections. In a second treatment study, the slight, but statistically significant, prolongation of survival by intracranial virus injection, irrespective of pre-immunization status, was reproduced. MST was 19 days (range 17-20 days) in −/− animals, 22 days in −/+ animals (range 19-26 days) and 21 days (range 17-39 days) in +/+ animals (P = 0.03 for −/− versus −/+ and P = 0.02 for −/− versus +/+). In both −/+ and +/+ groups, GCV treatment of half of the group did not significantly affect survival as compared with the half of the group that did not receive GCV treatment. MST in −/+ animals treated with GCV was 22.5 days (range 20-26 days) versus 20.5 days (range 19-25 days) without GCV; MST in +/+ animals was 20 days (range 17-39 days) with GCV as opposed to 21.5 days without GCV (range 17-39 days). Although not statistically significant, there seemed to be a tendency for improved survival with GCV treatment in nonimmunized animals but not in immunized animals.
. hrR3. Animals were immunized or shamimmunized with hrR3 on day 0, injected intracranially with 40 000 D74 glioma cells on day 21, and injected intratumorally with hrR3 or medium on day 25. Nonimmunized, hrR3-treated animals (−/+) 12 h (a), 1 day (c), 2 days (e) and 5 days (g) after intratumoral virus injection. hrR3-immunized, hrR3-treated animals (+/+) 12 h (b), 1 day (d), 2 days (f) and 5 days (h) after intratumoral virus injection. Sections were immunostained for HSVTK and counterstained with methylgreen, × 100 magnification (insert × 400).
PCR analysis of HSV virus sequences in internal organs DNA samples extracted from the liver, kidney, lung and small intestine of two animals per treatment group were analyzed by PCR for the presence of the HSV-1 ICP27 gene 2 days after intracranial injection of hrR3 (Figure 4) . Repeated PCR analysis revealed that 2 days after intracranial injection of virus in nonimmunized animals, this viral gene was detectable in all liver, lung and kidney samples ( Figure 4) . Additionally, the ICP27 gene was detected in eight of 14 assays in small intestine samples of these animals. However, the ICP27 gene was not reproducibly detected in tissue specimens from two immunized animals 2 days after intracranial virus injection. ICP27 was detected in the kidneys in two of 12 assays, in the liver in three of 12 assays, in the gut in three of 12 assays and in the lung in eight of 11 assays. The sporadic and inconsistent detection of ICP27 in internal organs of immunized animals may reflect a low concentration of the ICP27 gene, near the detection limit of this PCR. Kidney, small intestine, lung and liver samples of −/− animals were all negative except for the liver of one animal which proved ICP27 positive in two of nine tests. This could have resulted from contamination during the tissue preparation process or crossinfection between animals in the animal facility.
Discussion
This study demonstrates that pre-existing anti-HSV-1 immunity substantially decreases the extent of gene transfer by a HSV vector to intracranial rat gliomas, but does not completely abolish it. There was no apparent increase in neurotoxicity caused by the inflammatory response within the brain associated with a pre-existing anti-HSV-1 immune response. Furthermore, the presence of a pre-existing immunity to HSV-1 reduced the extent of the spread of the virus to other tissues. These findings support the potential utility of replication-conditional Since rodents are not a natural host for HSV-1, rats do not have pre-existing immunity to the virus, in contrast to most humans. To study the effectiveness and potential toxicity of HSV-1-mediated gene transfer under conditions of a pre-existing HSV-1 immunity, rats were immunized with the replication-conditional HSV-1 vector, hrR3, before intracranial vector application. As an index of a strong anti-HSV immune reaction, high titers of neutralizing antibodies were demonstrated after intraperitoneal immunization. High titers of neutralizing antibodies in the serum persisted for over 3 weeks. HSV-1 vector was injected into intracranial gliomas in these animals at a time when the levels of neutralizing antibodies were at their peak in order to evaluate gene transfer in a 'worst case' scenario. These conditions model those in humans who have high antibody titers associated with recurrent infections of wild-type HSV-1. 17 In our model, the intracranial administration of the vector also caused a rapid rise of neutralizing antibody titers in both immunized and nonimmunized rats.
HSV-1 immunization of animals decreased, but did not block virus infection of tumor cells. Within 12 h of intratumoral virus injection, during primary infection of tumor cells by hrR3, HSVTK and ␤-galactosidase expressing tumor cells were substantially fewer in immunized, as compared with nonimmunized, animals. However, the length of transgene expression was similar in immunized and nonimmunized animals. Reduced efficiency of initial gene transfer to glioma cells in immunized animals is probably mediated by neutralizing antibodies, which are directed mainly against HSV-1 envelope glycoproteins. 18, 19 The present study is the first to analyze the influence of neutralizing antibodies in the setting of HSV-1 vector application to experimental brain tumors. In previous studies, the influence of the antiviral immune response on the spread of HSV infection was analyzed mainly in model systems using mucocutaneous or intraocular application of wild-type virus to nontumor-bearing animals. 20, 21 The present model has the particular feature that direct intracranial injection of HSV-1 vectors uniformly leads to tissue damage and subsequent influx of serum into the needle track. Thus, in pre-immunized animals, neutralizing antibodies in the serum can block the initial viral infection of tumor cells. This situation models that anticipated in future gene therapy of human brain tumors in which recombinant HSV-1 vectors will be injected into the resection cavity or the infiltrating edge of the tumor, as in ongoing clinical trials using other virus vectors. 22 The inhibition of glioma cell infection by neutralizing antibodies might be compensated for, at least in part, by inoculation of high titers of vector. In this rat brain model the lack of HSVTK-positive cells 10 days after infection (in both immunized and nonimmunized animals) could be explained by a cellular anti-HSV-1 immune response to infected cells or death of tumor cells due to virus infection. In mouse models, neutralizing antibodies only partially protect against HSV-1 infection and the clearance of virus-infected cells is uniformly associated with HSV-1-specific cytotoxic T lymphocytes (CTL). 21 In contrast to neutralizing antibodies, CTL react not only against envelope glycoproteins, but also against immediate-early viral proteins, [23] [24] [25] which are expressed early in infection even with nonreplicative HSV-1 mutants. The CTL response to the vector and the transgenes probably did not limit the period of transgene expression in our model, as infection of D74 glioma cells with hrR3 did not lead to a productive infection and the expression of transgenes, lacZ and HSVtk, which are transcribed from early viral promotors, was probably shut down before the CTL response was effective. Although expression of viral antigens alone can lead to eradication of vector-infected cells, as shown for adenovirusmediated gene therapy to the liver, 26 cellular immune responses may also be raised against xenogeneic transgenes, 27, 28 including marker genes such as E. coli lacZ.
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Although the particular contribution of different antigenic components to reduced transgene expression in immunized animals has yet to be determined, a marked influx of inflammatory cells consisting of lymphocytes, granulocytes and macrophages was observed after intratumoral injection of the vector in both immunized and nonimmunized animals. Although the inflammatory infiltrate was not further subtyped, the presence of CD4 + and CD8 + lymphocytes and dendritic cells in these infiltrates can be inferred from previous studies investigating the immune response to an HSV-1 vector injected into rodent brain. 30 The inflammatory infiltrate observed in our study was clearly due to an immune reaction to the vector since D74 gliomas alone -which have low immunogenicity in syngeneic hosts -did not evoke an immune response. 14 In immunized animals, the inflammatory cell infiltrate appeared sooner and was more abundant than in nonimmunized animals. This immune response subsided earlier in immunized compared with nonimmunized animals, as demonstrated by the lack of ED-1 staining macrophages in immunized animals on day 10, when nonimmunized animals still showed positive cells (Figure 3f and g ).
The present study focuses on gene marking in a rat brain tumor model. The findings have implications for the therapeutic application of HSV-1 vectors to human glioblastomas, where the immune response to the virus would be likely to diminish gene delivery substantially. The most notable observation was the marked decrease in initial gene transfer to tumor cells in pre-immunized animals as compared with nonimmunized animals. The initial infection of target cells sets the stage for any further virus propagation and accompanying oncolysis. However, in the D74 glioma model although the prolongation of survival time by intratumoral HSV-1 vector application was small (11%), it was similar in both immunized and nonimmunized animals. The small prolongation of survival, as compared with studies using the 9L glioma model with hrR3, 5 probably reflects both the low infectability of D74 by hrR3, as shown here in culture, and the low inherent immunogenicity of the D74 glioma in its syngeneic host, 14 in contrast to the 9L and other glioma models. 5, 7, 31, 32 The low immunogenicity of the D74 glioma cells is comparable, however, with human glioblastomas which have limited antigen presentation and down-regulate systemic immune responses. 33 Although D74 is not as infectable with HSV-1 as human glioma cells 34 or some other rat glioma cell lines, such as 9L, there was substantial infection and notable oncolysis of D74 cells in culture at an MOI of 100. This MOI is comparable with that used in vivo, as 10 8 p.f.u. hrR3 were injected into about 10 6 glioma cells (assuming a doubling time of 24 h for the 40 000 glioma cells injected 5 days previously). Furthermore, pre-existing immunity to HSV-1 did not appear to reduce survival time. It is possible that the overall fewer number of hrR3-infected glioma cells in immunized animals might have been compensated for by an immune reaction to tumor antigens costimulated by the immune response to HSV-1. This effect, sometimes referred to as 'xenogenization', 35 results from the immune stimulation by enhanced cytokine secretion, here in the context of HSV-1-mediated glioma cell lysis. Viral infection can serve as a nonspecific adjuvant and has been used as a component in tumor vaccination therapy. 36 Treatment with GCV did not yield additional prolongation of survival in animals injected intratumorally with hrR3, as it has in 9L tumor models. 5, 7 This might be due to the relatively late start of GCV treatment (day 7) when only few HSVTK-positive cells are present in tumor. However, GCV treatment can be regarded as an important safety measure to help control replication and spread of HSV-1 vectors throughout the body.
Despite the potential hazard of a strong inflammatory reaction to the virus in the brains of immunized animals, which could lead to high cytokine release and edema, these animals did not fare worse in health as compared with nonimmunized animals. No histologic evidence of toxicity to the normal brain tissue was seen in immunized or nonimmunized animals. In fact, pre-existing HSV immunity may also be beneficial in limiting the spread of the virus to normal tissues beyond the CNS, as indicated by PCR analysis of peripheral tissues in immunized as compared with nonimmunized animals.
The findings of this study are not only pertinent to HSV-mediated gene therapy of brain tumors, but also for therapy of other CNS diseases. Gene delivery to neurons and glia should also be reduced to some extent because of neutralizing antibodies to HSV-1, which have been detected in 40-90% of humans. 12, 13 Injection into an intracranial tumor and into normal brain are comparable in the following ways: (1) the injection of the vector will cause some tissue damage and influx of serum and will thus allow neutralizing antibodies to come in contact with the vector; and (2) when a recombinant HSV virus is used as the vector (or the helper virus in an HSV amplicon system), viral gene expression is likely to occur and elicit a cellular immune response against infected cells. However, herpes amplicon vectors can also be produced in a helper virus-free system, 37 in which case there is no de novo synthesis of HSV proteins after infection.
Using such vectors, the HSV-specific cellular immune reaction against infected cells should be essentially nil.
Reduced gene transfer in immunized hosts is a feature that HSV vectors share with adenoviral vectors. Evaluation of adenoviral gene transfer to liver, lung and muscle in rodents has revealed the immune-mediated elimination of cells expressing transgenes over weeks and markedly impaired gene delivery in cases of repeated vector application. [38] [39] [40] After injection to the brain, a relatively immunoprivileged site, the immune reaction against low amounts of adenovirus vectors and transgenes can be weak enough to allow transgene expression over months. 41, 42 Subsequent subcutaneous re-infection with adenovirus, however, can induce a systemic immune response which is strong enough to suppress adenovirus protein and transgene expression within the brain to undetectable levels and to induce autoimmune demyelination within 2 weeks. 43, 44 In conclusion, this study demonstrates a substantial reduction, but nevertheless continued feasibility of gene transfer by a mutant HSV-1 vector under conditions of strong anti-HSV-1 immunity. This anti-HSV-1 immunity could have some benefit in therapeutic schemes as it should lower the nonspecific toxicity of the vector and may enhance immune recognition of tumor antigens. Still this primed immune response to the virus will, no doubt, limit oncolysis by replication-conditional HSV-1 vectors. Therefore, it becomes important to 'arm' the vectors with other therapeutic genes which have a broad bystander effect to maximize tumor cell killing in the context of limited tumor cell infection. HSV immunity itself does not appear to be a principle obstacle to future gene therapy of brain diseases using HSV vectors.
Materials and methods
Virus and cells
The mutant HSV-1 vector, hrR3, was obtained from Dr S Weller (University of Connecticut Medical School, CT, USA). 6 It has an insertion of the E. coli lacZ gene into the UL39 locus coding for the large subunit of ribonucleotide reductase/infected cell protein (ICP) 6. LacZ expression is driven by the ICP6 early promotor. The vector was passaged on African green monkey Vero cells and viral titers were obtained by plaque assays in Vero cell monolayers. 45 Virus stocks of 10 10 p.f.u./ml were stored at −80°C and thawed immediately before use. Procedures involving virus were performed in accordance with the guidelines issued by the Harvard Office of Biological Safety.
The D74 rat glioma line was originally cloned from an undifferentiated neoplasm, which was induced transplacentally by administration of N-nitrosourea to a pregnant Fischer rat. 46 The T98G human glioma line was established from a human glioblastoma. 47 Tumor cells were grown in Dulbecco's modified Eagle's medium (DMEM) containing 10% fetal calf serum, 100 U/ml penicillin, and 100 g/ml streptomycin (GIBCO, Gaithersburg, MD, USA) at 37°C in 5% carbon dioxide.
To determine the infectability of D74 cells with hrR3, 10 000 cells were plated in 24-well plates in duplicate and infected with varying p.f.u. of hrR3 (MOI 0.1, 1, 10 and 100). Sixteen and 48 h later, cells were washed with phosphate-buffered saline, pH 7.4 (PBS), fixed in ethanol, and stained for ␤-glactosidase for 4 h at 37°C in the X-gal staining solution containing 5 mm potassium ferrocyanide, 5 mm potassium ferricyanide, 2 mm magnesium chloride, 1 mg/ml X-gal (Fisher, Pittsburgh, PA, USA) and 2.5% dimethyl-sulfoxide (Sigma, St Louis, MO, USA) in PBS. 48 Five different fields per well (× 100 magnification) were counted to assess the percentage of lacZ + cells. Likewise, human T98 glioma cells were assayed for lacZ expression 16 h after infection with hrR3 (MOI 1, 3, 10, 30 and 100) .
The oncolytic ability of hrR3 on D74 cells was tested in culture using six-well plates. Sixty thousand D74 were plated per well in triplicate. Three wells were re-counted 1 day later, whereas other wells were infected with hrR3 at an MOI of 100. To some of the wells, 1 g/ml ganciclovir (GCV, Cytovene-IV, Hoffmann La Roche, Nutley, NJ, USA) was added on day 3 after infection. Uninfected cells which were not treated with GCV served as controls. On days 3 and 6 the number of viable cells per well was determined by counting using a Coulter Counter (Coulter Electronics, Hialeah, FL, USA) and trypan blue exclusion (Sigma) . To analyze the replication of hrR3 in D74 cells, cells were plated in triplicate and infected as described above; on days 3 and 5 cells were scraped, three times frozen and thawed, sonicated and assayed in a standard plaque assay.
Animal studies
Animal studies were performed in accordance with the guidelines issued by the Massachusetts General Hospital Subcommittee on Animal Care. Viral inoculation and care of animals harboring viruses were performed in approved viral vector rooms.
Male CD Fischer rats, weighing 250-300 g were obtained from Charles River Laboratories, Wilmington, MA, USA. For anti-HSV-1 immunization, animals were injected intraperitoneally with 10 8 p.f.u. hrR3 in 100 l DMEM or sham-vaccinated with 100 l DMEM alone. On day 21 after immunization all animals were injected intracranially with 40 000 D74 glioma cells in 2 l DMEM. For this procedure, animals were anesthetized by intraperitoneal injection with 800 l of a solution consisting of two parts bacteriostatic 0.9% NaCl (Abbott, IL, USA), and one part each of 20 mg/ml xylazine (Rompun; Miles, KA, USA) and 100 mg/ml ketamine (Ketalar; ParkeDavis, NJ, USA). After positioning the animals in a stereotactic apparatus (Kopf, Tujunga, CA, USA), a midline skin incision was made, and a burr hole was drilled at 2 mm rostral and 2 mm right of bregma. Cells were injected over a period of at least 2 min to a depth of 3.5 mm from the dura using a Hamilton syringe. After retracting the needle over 2 min, the burr hole was closed with bone wax (Ethicon), and the wound was washed with Betadine (Purdue Frederick, Norwalk, CT, USA). On day 25, animals were re-anesthetized and injected intratumorally through the same burr hole with 10 8 hrR3 in 10 l DMEM, or 10 l DMEM alone. Animals were divided in three different treatment groups: (1) both intraperitoneal immunization and intratumoral injection of hrR3 (+/+); (2) intraperitoneal sham-immunization and intratumoral injection of hrR3 (−/+); and (3) both intraperitoneal and intratumoral injection with medium alone (−/−).
For determination of neutralizing anti-HSV-1 antibody titers, blood samples from two animals per treatment group were drawn from the tail vein of anesthetized animals before immunization and 9, 18, 25, 27, 30 and 35 days after immunization.
For histological analysis, in the first experiment two animals per group were killed at 12, 24 and 48 h after intracranial virus injection by deep anesthesia with at least 2 ml of the ketamine/xylazine solution (i.p.) and subsequent perfusion with a 4% paraformaldehyde solution in PBS (4% PFA). The brain, liver, lung, kidney and small intestine of all animals were removed and postfixed in 4% PFA for 2 days, cryoprotected in 30% sucrose in PBS, and frozen at −80°C. In a second experiment two animals per treatment group were killed at 2, 5 and 10 days after intracranial virus injection; brains and internal organs were preserved as described above.
In the first therapeutic study the treatment groups, (−/−), (−/+) and (+/+), comprised a total of 11 animals. In a second experiment, the control consisted of eight animals in the −/− group, with 15 animals in the −/+ group and 16 animals in the +/+ group. Virus-treated groups were subdivided into two groups of eight or seven animals each and one from each subgroup was treated twice daily with intraperitoneal injections of 7.5 mg GCV from day 7 to day 14 after intracranial virus injection. Animals were observed daily and killed by carbon dioxide inhalation at the stage of terminal disease. (One −/− animal with a survival time of 32 days was excluded from this statistical analysis, as a marked reflux of tumor cell suspension during intracranial injection indicated that fewer tumor cells were implanted to this animal.) Survival distributions of different treatment groups were compared using the log-rank test.
Histology and immunohistochemistry
Brains were sectioned at 12 m using a cryostat and stained with hematoxylin and eosin (HE). For ␤-galactosidase staining, mounted slices were placed for 24 h at 37°C into X-gal staining solution (see above). The sections were washed with PBS and counterstained with neutral red. Immunohistochemistry was performed using standard biotin-avidin-bound peroxidase techniques (Vectastain ABC kit; Vector, Burlingame, CA, USA) and primary antibodies against HSVTK (rabbit polyclonal, dilution 1:500, gift of Dr W Summers, Yale University School of Medicine, New Haven, CT, USA) and the ED-1 antibody, which recognizes an epitope on macrophages and monocytes (mouse monoclonal, dilution 1:200, Serotec, Washington, DC, USA).
To quantify the extent of HSVtk and lacZ gene transfer to intracranial D74 tumors and their immediate surroundings, two to four tumor cross-sections per animal were analyzed using a video imaging system by an investigator blinded to the treatment protocol. For each section, four high-power fields containing tumor tissue were evaluated for the percentage of area covered with cells staining positive for lacZ or HSVTK in relation to the total area covered by tissue and named 'percentage of lacZ-positive area' or 'percentage of HSVTK-positive area', respectively. The mean value of the four high power fields per section was determined. Subsequently, the mean value of the two to four sections analyzed for 'percentage of lacZ-positive' or 'HSVTK-positive area' was calculated for each animal. The values of the two animals per treatment group and time-point were then averaged and the standard error was determined.
Assay for titers of neutralizing anti-HSV antibodies
Neutralizing antibody titers against hrR3 were detected using a modification of a complement-dependent plaque inhibition assay. 19 Two-fold serial dilutions in PBS were prepared from serum samples pooled from two animals at each time-point. Positive control serum was obtained from a mouse 29 days after immunization against wildtype HSV-1 KOS by inoculation of 2 × 10 6 p.f.u. per eye to both eyes (provided by D Garber, Harvard Medical School). Lyophilized rabbit complement (Low-Tox rabbit complement, Accurate, Westbury, NY, USA) was reconstituted in 2 ml PBS and mixed with equal volumes of a 10 6 p.f.u./ml hrR3 virus stock. Aliquots of 120 l of each serum dilution were mixed with 120 l virus/complement solution and incubated for 2 h at 37°C. Virus/complement solution alone, and virus alone served as controls. After adding 660 l PBS, samples were incubated in duplicate on confluent Vero cells in 24-well plates. After 1 h incubation, 1.5 ml DMEM containing 5% FCS, P/S and 1% human immunoglobulin (Massachusetts Public Health Biologic Laboratories, Boston, MA, USA) were added to each well. Viral plaque formation was assessed 2 days later after Giemsa staining (Sigma). The neutralizing antibody titer was defined as the highest serum dilution that reduced the number of plaques by 50% or more compared with the negative controls.
Polymerase chain reaction (PCR) for HSV sequences in blood and tissue samples Tissue samples were thawed and cubes of about 2 mm in each dimension were homogenized by mincing with a razor blade and grinding between two slides, resuspended in 1 ml PBS, and frozen at −20°C. Tissue homogenates were treated with final concentrations of 0.5% SDS (Sigma) and 100 g/ml Proteinase K (Boehringer Mannheim, Mannheim, Germany) for 2-3 h at 37°C. The DNA was extracted with equal volumes of phenolchloroform, precipitated with 2 volumes of ice cold ethanol and 1/10 3 m sodium acetate, pH 5.2, and resuspended in 20 l H 2 O; 2 l aliquots of this mixture were used for each PCR analysis. The oligonucleotide primers for PCR analysis were obtained from GIBCO, and were chosen from sequences in the ICP27 gene of HSV-1: upstream primer ICP27-5: 5Ј-GTCGACCGCATC AGCGAGAGC-3Ј (114 517-114 537), and downstream primer ICP27-3: 5Ј-CGATGTGACTGGCCGTCAACT-3Ј (115 198-115 219). PCR was carried out on a total 25 l reaction mix, containing 2 l of template DNA, 5 l dNTPs (GIBCO) 2.5 l reaction buffer (GIBCO), 0.25 l of each primer, and 0.125 l Taq polymerase (New England Biolabs, Beverly, MA, USA). The PCR reaction started with 10 min at 72°C, followed by 30 cycles with denaturation at 94°C for 40 s, primer annealing at 65°C for 1 min, and primer extension at 72°C for 1 min. The size of PCR products was confirmed by electrophoresis in a 1.2% agarose gel and visualization with ethidium bromide. To exclude contamination, a reaction mix without DNA was run in parallel. DNA from each individual internal organ was assayed in three to six independent PCR experiments.
